Praxis Precision Medicines (PRAX) officer receives RSUs, options and tax withholding

Rhea-AI Filing Summary

Praxis Precision Medicines, Inc. reported insider equity transactions by Principal Accounting Officer Lauren Mastrocola. On January 8, 2026, she received 3,750 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of January 8, 2026. She was also granted a stock option for 7,500 shares of common stock at an exercise price of $294.38 per share, vesting over four years with 25% on January 8, 2027 and the remainder in 36 monthly installments. On January 10, 2026, 367 shares of common stock were withheld at $288.45 per share to satisfy tax withholding obligations related to vesting of previously reported restricted stock units, leaving her with 13,789.656 shares of common stock held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mastrocola Lauren

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		A(1)		3,750	A	$0	14,156.656	D
Common Stock	01/10/2026		F(2)		367	D	$288.45	13,789.656	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$294.38	01/08/2026		A		7,500		(3)	01/08/2036	Common Stock	7,500	$0	7,500	D

Explanation of Responses:

1. Ms. Mastrocola was awarded 3,750 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on the one-year anniversary of the vesting commencement date of January 8, 2026. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

2. Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units.

3. The shares underlying this stock option vest over a four-year period, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did PRAX Principal Accounting Officer Lauren Mastrocola report?

Lauren Mastrocola reported receiving 3,750 restricted stock units and a stock option for 7,500 shares of Praxis Precision Medicines common stock on January 8, 2026, plus a tax-related share withholding transaction on January 10, 2026.

How do the 3,750 restricted stock units granted to the PRAX officer vest?

The 3,750 restricted stock units vest in equal annual installments over four years, starting on the one-year anniversary of the January 8, 2026 vesting commencement date. Each unit represents a right to receive one share of common stock, settled only in shares.

What are the terms of the 7,500 share stock option granted by Praxis Precision Medicines (PRAX)?

The stock option covers 7,500 shares of common stock with an exercise price of $294.38 per share. It vests over four years: 25% on January 8, 2027 and the remaining 75% in 36 equal monthly installments thereafter, subject to continued service.

Why were 367 PRAX shares reported as disposed of at $288.45?

The 367 shares of common stock reported as disposed of at $288.45 per share on January 10, 2026 were shares withheld by Praxis Precision Medicines to satisfy tax withholding obligations related to vesting of previously reported restricted stock units.

How many PRAX common shares does Lauren Mastrocola hold after these transactions?

After the reported transactions, Lauren Mastrocola beneficially owns 13,789.656 shares of Praxis Precision Medicines common stock directly, according to the filing.

Are the equity awards to the PRAX Principal Accounting Officer part of a compensation package?

The filing describes grants of restricted stock units and a stock option with multi-year vesting schedules for the Principal Accounting Officer, which are typical components of an executive equity compensation program.